Rheumatoid Arthritis Radiographic Progression May Be Surrogate Marker
Executive Summary
Slowing of radiographic progression in rheumatoid arthritis could serve as a surrogate marker for accelerated approval under FDA's revised "Draft Guidance for Industry on Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis" released March 18.